VH4127
VH4127 is a cyclic peptide targeting the low density lipoprotein receptor (LDLR) with a KD of 18 nM for hLDLR. VH4127, bearing non-natural amino acid residues, specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C40H71N15O9S4
- Masse moléculaire:1034.35
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
|
hLDLR 18 nM (Kd) |
Chemical Information
-
Masse moléculaire 1034.35
-
Formule C40H71N15O9S4
-
Sequence
Pr-cyclo[{d-Cys}-Met-Thz-Arg-Leu-Arg-Gly-Pen]-NH2
-
Sequence Shortening
Pr-cyclo[{d-Cys}-M-Thz-RLRG-Pen]-NH2
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Xue Yang, et al. Preparation and In Vitro Validation of a Cucurbit[7]uril-Peptide Conjugate Targeting the LDL Receptor. J Med Chem. 2023 Jul 13;66(13):8844-8857. [Content Brief]
[2]. Angélina Acier, et al. LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma. Commun Biol. 2021 Aug 19;4(1):987. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)